Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
J Affect Disord. 2020 Mar 15;265:395-401. doi: 10.1016/j.jad.2020.01.032. Epub 2020 Jan 15.
Effective treatment requires regular follow-up and monitoring of symptoms. We investigated sensitivity to change and minimal clinically important difference of the Generalized Anxiety Disorder Scale (GAD-7).
This study included all participants from a multisite trial of chronic depression. Baseline and follow-up (12 and 48 weeks) data were used to assess treatment response. Effect sizes (ES) and standardized response means (SRM) of pre- and post-GAD-7 mean changes were calculated for subgroups of patients, who did or did not improve according to ratings in the Hamilton Rating Scale for Depression (HRSD-24).
N = 261 patients were included in the analyses. In the subgroup of patients who improved according to HRSD-24, GAD-7 scores were significantly lower after 12 weeks (t = -6.31, df = 120, p < .001; ES = -0.51, SRM = -0.57), and 48 weeks of treatment (t = -12.68, df = 141, p < .001; ES = -1.0, SRM = -1.7), when compared to admission. In the group who worsened, GAD-7 scores were significantly higher after 12 weeks (t = 2.96, df = 41, p = .005; ES = 0.30, SRM = 0.46), and increased after 48 weeks (t = 1.99, df = 21, p = .059; ES = 0.37, SRM = 0.43), when compared to baseline. The unchanged group showed no significant difference between baseline and follow-up. MCID was estimated 4 points on the GAD-7 total score.
Confirmation of these findings and further investigation of the GAD-7 in populations and trials focusing on anxiety-specific treatment is highly recommended.
Results show that the GAD-7 is sensitive to detect change in psychopathology over the course of treatment.
有效的治疗需要定期随访和监测症状。我们研究了广泛性焦虑障碍量表(GAD-7)的变化敏感性和最小临床重要差异。
本研究纳入了来自多中心慢性抑郁症试验的所有参与者。使用基线和随访(12 周和 48 周)数据来评估治疗反应。根据汉密尔顿抑郁评定量表(HRSD-24)的评分,计算了 GAD-7 均值变化的预和后效应大小(ES)和标准化反应均值(SRM),用于亚组患者。
共纳入 261 例患者进行分析。在根据 HRSD-24 改善的患者亚组中,GAD-7 评分在 12 周后显著降低(t=-6.31,df=120,p<0.001;ES=-0.51,SRM=-0.57),48 周治疗后(t=-12.68,df=141,p<0.001;ES=-1.0,SRM=-1.7),与入院时相比。在病情恶化的患者中,GAD-7 评分在 12 周后显著升高(t=2.96,df=41,p=0.005;ES=0.30,SRM=0.46),48 周后升高(t=1.99,df=21,p=0.059;ES=0.37,SRM=0.43),与基线相比。未改变的组在基线和随访之间没有显著差异。GAD-7 总分的 MCID 估计为 4 分。
强烈建议在关注焦虑特异性治疗的人群和试验中确认这些发现,并进一步研究 GAD-7。
结果表明,GAD-7 能够敏感地检测治疗过程中心理病理学的变化。